DNTH NASDAQ
Dianthus Therapeutics, Inc.
1W: -0.6%
1M: -6.8%
3M: +80.5%
YTD: +115.9%
1Y: +335.1%
3Y: +743.2%
5Y: -58.2%
$88.72
+3.05 (+3.56%)
After Hours: $89.36 (+0.64, +0.72%)
Weekly Expected Move ±5.1%
$77
$82
$86
$91
$95
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.6B
52W Range16.64-96.5
Volume527,630
Avg Volume948,363
Beta0.09
Dividend—
Analyst Ratings
Company Info
CEOMarino Garcia
Employees78
SectorHealthcare
IndustryBiotechnology
IPO Date2018-06-21
Websitedianthustx.com
7 Times Square
New York City, NY 10036
US
New York City, NY 10036
US
929-999-4055
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Latest News
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics GAAP EPS of -$0.85 beats by $0.23, revenue of $0.46M beats by $0.1M
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Soteropoulos Paula | S-Sale | 599 | $85.47 | 2026-05-08 |
| Soteropoulos Paula | M-Exempt | 599 | $8.44 | 2026-05-08 |
| Soteropoulos Paula | M-Exempt | 599 | $8.44 | 2026-05-08 |
| Savitz Ryan | M-Exempt | 8,224 | $17.88 | 2026-04-09 |
| Savitz Ryan | M-Exempt | 8,224 | $17.88 | 2026-04-09 |